Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01529307 · ClinicalTrials.gov registry record · Phase 1
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01529307 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT01529307, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.
Interventions
- DRUG TAS266
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2012-06 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01529307
The ClinicalTrials.gov registry entry for NCT01529307 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS266 is the first listed.
NCT01529307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01529307 about?
NCT01529307 is a clinical study titled "First in Human Trial of TAS266 in Patients With Advanced Solid Tumors". This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.
What is the current status of trial NCT01529307?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2012-06. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01529307?
The interventions under investigation include: TAS266 (DRUG).
Who is sponsoring clinical trial NCT01529307?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.